|
|
|
|
| LEADER |
01547nam a2200253 u 4500 |
| 001 |
EB002010930 |
| 003 |
EBX01000000000000001173829 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
220201 r ||| eng |
| 245 |
0 |
0 |
|a CADTH Canadian Drug Expert Committee recommendation: Etonogestrel extended-release subdermal implant (Nexplanon -- Merck Canada Inc.)
|h Elektronische Ressource
|b indication : prevention of pregnancy for up to three years
|
| 246 |
3 |
1 |
|a Etonogestrel extended-release subdermal implant (Nexplanon -- Merck Canada Inc.)
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2020, October 2020
|
| 300 |
|
|
|a 1 PDF file (9 pages)
|
| 710 |
2 |
|
|a CADTH Canadian Drug Expert Committee
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 500 |
|
|
|a "Final."
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK567287
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 580
|
| 520 |
|
|
|a Etonogestrel extended-release subdermal implant has a Health Canada indication for the prevention of pregnancy. Etonogestrel is the biologically active metabolite of desogestrel, a progestagen widely used in oral contraceptives. This radiopaque implant is a longacting hormonal contraceptive that contains 68 mg of etonogestrel. The Health Canada-approved dose is for a single implant that is inserted subdermally and can be left in place for three years
|